Nastaoupil LJ, Sinha R, Byrtek M, Zhou X, Taylor M, Friedberg J, Link B, Cerhan J, Dawson K, Flowers C. Characteristics and effectiveness of rituximab (R) maintenance regimens among US patients diagnosed with follicular lymphoma (FL) 2004-2007. Poster presented at the 17th Congress of the European Hematology Association; June 14, 2012. Amsterdam, The Netherlands. [abstract] Haematologica. 2012 Jul 16; 97(s1):95-6. Previously presented at the 53rd Annual Meeting of the American Society of Hematology.
Lewis S, Price M, Mordin M, Dwyer K, Heekin R, Yates P, O'Brien S, Beverland D. Assessing performance following primary total knee arthroplasty: development of the patient's knee implant performance (PKIP) measure. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 7, 2012. [abstract] Value Health. 2012 Jun 1; 15(4):A70.
Petrillo J, Cano S, McLeod LD, Coon CD. What is the value of classical test theory, item response theory, and Rasch measurement theory in the development of patient-reported outcome instruments? Presented at the 2012 ISPOR 17th Annual International Meeting; June 2012. Washington, DC.
Gnanasakthy A, Lewis SA, Clark MJ, Mordin MM, Evans E, DeMuro-Mercon CJ. The impact of primary endpoints on patient-reported outcome label claims. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 2012.
Coon CD, Fehnel SE, Davis KH, Runken MC, Beach ME, Cady RK. The development of a survey to measure completeness of response to migraine therapy. Headache. 2012 Apr 1;52(4):550-72.
DiBenedetti DB, Danchenko N, Francois C, Lewis SA, Davis KH, Fehnel SE. Development of a family functioning scale for major depressive disorder. Curr Med Res Opin. 2012 Mar 1;28(3):303-13.
Reau N, Hamzeh FM, Lentz E, Zhou X, Jensen D. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb;19(2):94-102.
Hareendran A, Gnanasakthy A, Winnette RM, Revicki D. Capturing patients' perspectives of treatment in clinical trials/drug development. Contemp Clin Trials. 2012 Jan;33(1):23-8.